Avantor, Inc. Faces Class Action Lawsuit Over Alleged Securities Fraud
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 29 2025
0mins
Source: Globenewswire
- Lawsuit Notification: Levi & Korsinsky LLP informs investors that Avantor, Inc. is facing a class action lawsuit for alleged securities fraud occurring between March 5, 2024, and October 28, 2025, aimed at recovering losses for affected investors.
- Allegations: The lawsuit claims that defendants concealed Avantor's weaker competitive positioning and the negative impacts from increased competition, resulting in materially false and misleading representations about the company's business and prospects.
- Investor Rights: Affected investors have until December 29, 2025, to request to be appointed as lead plaintiff to share in any potential recovery, with no out-of-pocket costs required to participate.
- Legal Team Strength: With 20 years of experience in securities litigation, Levi & Korsinsky has secured hundreds of millions for aggrieved shareholders, demonstrating its expertise and successful track record in complex securities cases.
Analyst Views on AVTR
Wall Street analysts forecast AVTR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVTR is 12.30 USD with a low forecast of 8.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
2 Buy
9 Hold
2 Sell
Hold
Current: 11.650
Low
8.00
Averages
12.30
High
17.00
Current: 11.650
Low
8.00
Averages
12.30
High
17.00
About AVTR
Avantor, Inc. is a life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. The Company’s segments include Laboratory Solutions and Bioscience Production. Within its segments, it sells materials and consumables, equipment and instrumentation and services and specialty procurement to customers in the biopharma and healthcare, education and government and advanced technologies and applied materials industries. Materials and consumables include ultra-high purity chemicals and reagents, lab products and supplies, highly specialized formulated silicone materials, customized excipients, and others. Equipment and instrumentation include filtration systems, virus inactivation systems, incubators, analytical instruments, and others. Services and specialty procurement include onsite lab and production, equipment, procurement and sourcing and biopharmaceutical material scale-up and development services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
